Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Covidien Closes In On Varicose Vein Market With $440 Mil. VNUS Buy

This article was originally published in The Gray Sheet

Executive Summary

Covidien will bolster its vascular business through the acquisition of varicose vein treatment marketer VNUS for $440 million

You may also be interested in...



Covidien Further Bulks Up Vascular Biz With Sapheon Buy

Just one week after inking a deal to buy neurovascular product firm Reverse Medical, Covidien announced the purchase of another vascular device maker, Sapheon, which focuses on venous disease treatments.

Medtronic And Covidien Continue Shopping In Advance Of Pairing

Medtronic and Covidien have announced two deals each in the past week. The two firms are set to be combined by early next year under a megadeal announced in June.

Covidien Makes Big Play In Endovascular With $2.6 Billion ev3 Deal

Covidien says its large international operations will further accelerate ev3's fast-growing neurovascular and peripheral vascular businesses following its planned $2.6 billion acquisition of the endovascular firm

Related Content

Topics

UsernamePublicRestriction

Register

MT027412

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel